Cidara Therapeutics (CDTX) News Today $98.51 -3.66 (-3.58%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$99.50 +0.99 (+1.00%) As of 10/8/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CDTX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Cidara Therapeutics (NASDAQ:CDTX) Shares Up 5.5% - Time to Buy?October 7 at 1:44 PM | marketbeat.comJMP Securities Maintains Cidara Therapeutics (CDTX) Market Outperform RecommendationOctober 4, 2025 | msn.comCidara Therapeutics (CDTX): Assessing Valuation as Phase 3 Trial for Influenza Preventative Expands to Broader Patient GroupsOctober 2, 2025 | finance.yahoo.comCidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative TherapeuticOctober 2, 2025 | globenewswire.comCidara Therapeutics (CDTX) Price Target Increased by 77.93% to 134.30September 30, 2025 | msn.comCidara Therapeutics, Inc. (CDTX) Accelerates Phase 3 Trial for Single-Dose Flu Antiviral CD388September 30, 2025 | finance.yahoo.comCidara Therapeutics (NASDAQ:CDTX) Sets New 12-Month High - Should You Buy?September 30, 2025 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Consensus Rating of "Buy" from BrokeragesSeptember 29, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Shares Up 5.9% After Analyst UpgradeSeptember 28, 2025 | americanbankingnews.comWhy Cidara Therapeutics Was Such a Healthy Stock TodaySeptember 26, 2025 | fool.comCidara Therapeutics (NASDAQ:CDTX) Stock Price Up 5.9% Following Analyst UpgradeSeptember 26, 2025 | marketbeat.comHC Wainwright Forecasts Strong Price Appreciation for Cidara Therapeutics (NASDAQ:CDTX) StockSeptember 26, 2025 | marketbeat.comGuggenheim Maintains Cidara Therapeutics (CDTX) Buy RecommendationSeptember 26, 2025 | msn.comCidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk PopulationsSeptember 25, 2025 | globenewswire.comCidara Therapeutics Expands Phase 3 Trial for CD388September 25, 2025 | msn.comCidara stock soars after FDA feedback on expanded Phase 3 trialSeptember 25, 2025 | investing.comCidara jumps after expedited late-stage trial plan for flu therapySeptember 25, 2025 | msn.comWhy Cidara Therapeutics, Already Up 173% This Year, Just Hit A Seven-Year HighSeptember 25, 2025 | msn.comNeedham & Company LLC Issues Positive Forecast for Cidara Therapeutics (NASDAQ:CDTX) Stock PriceSeptember 24, 2025 | marketbeat.comCidara Therapeutics Accelerates Phase 3 Study for CD388 Following FDA Feedback, Expands Study Population to Include Older AdultsSeptember 24, 2025 | quiverquant.comQCidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal InfluenzaSeptember 24, 2025 | globenewswire.comCidara Therapeutics (NASDAQ:CDTX) Sets New 1-Year High - Here's WhySeptember 24, 2025 | marketbeat.comCidara Therapeutics, Inc. $CDTX Shares Acquired by Goldman Sachs Group Inc.September 23, 2025 | marketbeat.comCidara Therapeutics price target raised to $123 from $45 at WBB SecuritiesSeptember 22, 2025 | msn.comWBB Securities Raises Cidara Therapeutics (NASDAQ:CDTX) Price Target to $123.00September 22, 2025 | marketbeat.comWill Positive CD388 Influenza Data Shift Cidara Therapeutics’ (CDTX) Outlook for Prevention Therapies?September 21, 2025 | finance.yahoo.comCidara's Flu Drug: A Phase 2 Triumph, A Phase 3 GauntletSeptember 20, 2025 | seekingalpha.comCidara Therapeutics (NASDAQ:CDTX) Hits New 12-Month High - Should You Buy?September 19, 2025 | marketbeat.comCidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV’s 8th AVG and 3rd IMRP 2025 MeetingSeptember 17, 2025 | markets.businessinsider.comCidara Therapeutics presents data on CD388 from Phase 2b NAVIGATE trialSeptember 17, 2025 | msn.comCidara Therapeutics Presents CD388 Efficacy and Safety Data from NAVIGATE Phase 2b Trial at ISRV ConferenceSeptember 17, 2025 | quiverquant.comQCidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV's 8th AVG and 3rd IMRP 2025 MeetingSeptember 17, 2025 | globenewswire.comInsider Selling: Cidara Therapeutics (NASDAQ:CDTX) Insider Sells 474 Shares of StockSeptember 16, 2025 | marketbeat.comNicole Negar Davarpanah Sells 474 Shares of Cidara Therapeutics (NASDAQ:CDTX) StockSeptember 16, 2025 | insidertrades.comCidara Therapeutics, Inc. (CDTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comAmerican Century Companies Inc. Purchases Shares of 10,409 Cidara Therapeutics, Inc. $CDTXSeptember 9, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Buys 620,046 Shares of Cidara Therapeutics, Inc. $CDTXSeptember 7, 2025 | marketbeat.comCheckpoint Capital L.P. Trims Stock Holdings in Cidara Therapeutics, Inc. $CDTXSeptember 6, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Has $416,000 Stock Holdings in Cidara Therapeutics, Inc. $CDTXSeptember 6, 2025 | marketbeat.comBVF Inc. IL Has $19.92 Million Stock Holdings in Cidara Therapeutics, Inc. $CDTXSeptember 5, 2025 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Given Consensus Rating of "Buy" by AnalystsSeptember 5, 2025 | marketbeat.comCidara Therapeutics to Present at Upcoming Investor Conferences in September 2025September 4, 2025 | quiverquant.comQCidara Therapeutics to Participate in September Investor ConferencesSeptember 4, 2025 | globenewswire.comADAR1 Capital Management LLC Has $451,000 Stock Position in Cidara Therapeutics, Inc. $CDTXSeptember 4, 2025 | marketbeat.comVestal Point Capital LP Acquires Shares of 504,542 Cidara Therapeutics, Inc. $CDTXSeptember 4, 2025 | marketbeat.comCidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV's 8th AVG and 3rd IMRP 2025 MeetingSeptember 3, 2025 | globenewswire.comCidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Above 50-Day Moving Average - Time to Sell?September 1, 2025 | marketbeat.comAberdeen Group plc Buys Shares of 120,879 Cidara Therapeutics, Inc. $CDTXAugust 24, 2025 | marketbeat.comCidara Therapeutics: Still Big Catalysts Ahead Following Impressive Ph2b ReadoutAugust 15, 2025 | seekingalpha.comCidara Therapeutics: Promising Trials Amidst Financial ChallengesAugust 13, 2025 | msn.com Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CDTX Media Mentions By Week CDTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CDTX News Sentiment▼0.540.63▲Average Medical News Sentiment CDTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CDTX Articles This Week▼54▲CDTX Articles Average Week Get the Latest News and Ratings for CDTX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Cidara Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Revolution Medicines News Today Grifols News Today Rhythm Pharmaceuticals News Today Avidity Biosciences News Today Abivax News Today Legend Biotech News Today Cytokinetics News Today Nuvalent News Today Axsome Therapeutics News Today TG Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CDTX) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
